Index | Gene Name Primary | Protein Name | Uniprot ID | Gene Name Synonym | Ligand Name | Structure | PDB Code | ligand desolvation | Ligand Structure | Compound Affinity nM |
1 | CFAB | Complement factor B | P00751 | BF BFD | jgt | Complement factor B protease domain in complex with the reversible inhibitor N-(2-bromo-4-methylnaphthalen-1-yl)-4,5-dihydro-1H-imidazol-2-amine. | 6qsw | 96.75 | | no data |
2 | CFAB | Complement factor B | P00751 | BF BFD | jgq | Complement factor B protease domain in complex with the reversible inhibitor 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid | 6rav | 88.43 | | no data |
3 | CFAB | Complement factor B | P00751 | BF BFD | jgn | Complement factor B protease domain in complex with the reversible inhibitor ((2S,4S)-1-((5,7-dimethyl-1H-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)methanol. | 6qsx | 94.42 | | no data |
4 | CFAD | Complement factor D | P00746 | DF PFD | j7b | Complement factor D in complex with the inhibitor 2-(2-(3'-(aminomethyl)-[1,1'-biphenyl]-3-carboxamido)phenyl)acetic acid | 6qmt | 89.81 | | no data |
5 | CFAD | Complement factor D | P00746 | DF PFD | j6t | Complement factor D in complex with the inhibitor (S)-2-(2-((3'-(1-amino-2-hydroxyethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)acetic acid | 6qmr | 87.62 | | no data |
6 | CFAD | Complement factor D | P00746 | DF PFD | e85 | Complement factor D in complex with the inhibitor 3-((3-((3-(aminomethyl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenol | 6fug | 70.01 | | no data |
7 | CFAD | Complement factor D | P00746 | DF PFD | e7h | COMPLEMENT FACTOR D COMPLEXED WITH COMPOUND 5 | 6fty | 78.68 | | no data |
8 | CFAD | Complement factor D | P00746 | DF PFD | e7e | COMPLEMENT FACTOR D COMPLEXED WITH COMPOUND 6 | 6ftz | 69.52 | | no data |
9 | CFAD | Complement factor D | P00746 | DF PFD | 8s2 | Complement factor D in complex with the inhibitor (2S,4S)-4-Amino-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxy-phenyl)-amide] | 5nb6 | 78.61 | | 500. |
10 | CFAD | Complement factor D | P00746 | DF PFD | 5w5 | COMPLEMENT FACTOR D IN COMPLEX WITH COMPOUND2 | 5fbe | 80.47 | | 14000. |
11 | CFAD | Complement factor D | P00746 | DF PFD | 5wc | COMPLEMENT FACTOR D IN COMPLEX WITH COMPOUND 5 | 5fck | 82.11 | | 6. |
12 | CFAD | Complement factor D | P00746 | DF PFD | qjs | COMPLEMENT FACTOR D IN COMPLEX WITH A REVERSIBLE INDOLE CARBOXYLIC ACID BASED INHIBITOR | 5mt0 | 79.4 | | 500000. |
13 | CFAD | Complement factor D | P00746 | DF PFD | m7o | COMPLEMENT FACTOR D IN COMPLEX WITH A REVERSIBLE BENZOIC ACID BASED INHIBITOR | 5mt4 | 85.36 | | 500000. |
14 | CFAD | Complement factor D | P00746 | DF PFD | 8rw | Complement factor D in complex with the inhibitor (S)-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxy-phenyl)-amide] | 5nar | 79.75 | | 500. |
15 | CFAD | Complement factor D | P00746 | DF PFD | 8rt | Complement factor D in complex with the inhibitor (S)-Pyrrolidine-1,2-dicarboxylic acid 1-[(1-methyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxy-phenyl)-amide] | 5nat | 79.44 | | no data |
16 | CFAD | Complement factor D | P00746 | DF PFD | 8rz | Complement factor D in complex with the inhibitor (1R,3S,5R)-2-Aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 2-[(1-carbamoyl-1H-indol-3-yl)-amide] 3-[(3-trifluoromethoxy-phenyl)-amide] | 5naw | 85.72 | | 50. |
17 | CFAD | Complement factor D | P00746 | DF PFD | 8nq | Complement factor D | 5nb7 | 83.63 | | 6. |
18 | CFAD | Complement factor D | P00746 | DF PFD | 8s5 | Complement factor D in complex with the inhibitor (2S,4R)-4-Fluoro-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxy-phenyl)-amide] | 5nba | 80.52 | | 50. |
19 | CFAD | Complement factor D | P00746 | DF PFD | e88 | Complement factor D in complex with the inhibitor (4-((3-(aminomethyl)phenyl)amino)quinazolin-2-yl)-L-valine | 6fuh | 80.78 | | no data |
20 | CFAD | Complement factor D | P00746 | DF PFD | e7w | Complement factor D in complex with the inhibitor 3-((3-((3-(aminomethyl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenol | 6fui | 80.26 | | no data |
21 | CFAD | Complement factor D | P00746 | DF PFD | e82 | Complement factor D in complex with the inhibitor (S)-3'-(aminomethyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-[1,1'-biphenyl]-3-carboxamide | 6fut | 83.72 | | no data |
22 | CMA1 | Chymase | P23946 | CYH CYM | kpk | Crystal Structure of the human Chymase with TJK002 | 4kp0 | 76.08 | | 2.24 |
23 | CMA1 | Chymase | P23946 | CYH CYM | 8w6 | Human chymase in complex with 3-(ethoxyimino)-7-oxo-1,4-diazepane derivative | 5yjp | 78.94 | | 240. |
24 | CMA1 | Chymase | P23946 | CYH CYM | 8w3 | Human chymase in complex with 7-oxo-3-(phenoxyimino)-1,4-diazepane derivative | 5yjm | 80.14 | | 21. |
25 | CMA1 | Chymase | P23946 | CYH CYM | 0bb | Crystal Structure of Human Chymase with Benzimidazolone Inhibitor | 3s0n | 65.75 | | 180. |
26 | CMA1 | Chymase | P23946 | CYH CYM | 1p9 | Crystal Structure of Human Chymase in Complex with Fragment Linked Benzimidazolone Inhibitor: (3S)-3-{3-[(6-bromo-2-oxo-2,3-dihydro-1H-indol-4-yl)methyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}hexanoic acid | 4k69 | 77.91 | | 40. |
27 | ELNE | Neutrophil elastase | P08246 | ELA2 | wqq | Neutrophil elastase inhibitors for the treatment of (cardio)pulmonary diseases | 5abw | 63.48 | | 17. |
28 | ELNE | Neutrophil elastase | P08246 | ELA2 | jjx | Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor | 5a0b | 62.06 | | 5. |
29 | ELNE | Neutrophil elastase | P08246 | ELA2 | iuy | Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor | 5a8x | 76.29 | | 6.5 |
30 | ELNE | Neutrophil elastase | P08246 | ELA2 | 151 | Crystal structure of human neutrophil elastase complexed with an inhibitor (GW475151) | 1h1b | 64.64 | | 0.16 |
31 | ELNE | Neutrophil elastase | P08246 | ELA2 | 2hy | Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor | 3q77 | 74.94 | | 6. |
32 | ELNE | Neutrophil elastase | P08246 | ELA2 | iul | Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor | 5a8z | 74.73 | | 28. |
33 | ELNE | Neutrophil elastase | P08246 | ELA2 | cqh | Crystal structure of highly glycosylated human leukocyte elastase in complex with a thiazolidinedione inhibitor | 6f5m | 81.36 | | no data |
34 | FA10 | Coagulation factor X | P00742 | | z34 | CRYSTAL STRUCTURE OF THE INHIBITOR ZK-807834 (CI-1031) COMPLEXED WITH FACTOR XA | 1fjs | 71.45 | | 0.11 |
35 | FA10 | Coagulation factor X | P00742 | | xwg | FACTOR XA - CATION INHIBITOR COMPLEX | 2y5f | 75.49 | | 2. |
36 | FA10 | Coagulation factor X | P00742 | | xmh | Human coagulation factor Xa in complex with M55124 | 1iqj | 70.05 | | no data |
37 | FA10 | Coagulation factor X | P00742 | | xmg | Human coagulation factor Xa in complex with M55125 | 1iqi | 76.74 | | no data |
38 | FA10 | Coagulation factor X | P00742 | | xmf | Human coagulation factor Xa in complex with M55143 | 1iqh | 76.37 | | no data |
39 | FA10 | Coagulation factor X | P00742 | | xme | Human coagulation factor Xa in complex with M55159 | 1iqg | 76.75 | | no data |
40 | FA10 | Coagulation factor X | P00742 | | xma | Human coagulation factor Xa in complex with M55532 | 1ioe | 72.25 | | no data |
41 | FA10 | Coagulation factor X | P00742 | | xld | Crystal Structure of 3-chloro-N-[4-chloro-2-[[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[[(4,5-dihydro-2-oxazolyl)methylamino]methyl]-2-thiophenecarboxamide Complexed with Human Factor Xa | 1mq6 | 74.99 | | 0.007 |
42 | FA10 | Coagulation factor X | P00742 | | xlc | Crystal Structure of 3-chloro-N-[4-chloro-2-[[(4-chlorophenyl)amino]carbonyl]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]-2-thiophenecarboxamide Complexed with Human Factor Xa | 1mq5 | 78.26 | | 1. |
43 | FA10 | Coagulation factor X | P00742 | | xbv | Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor | 2xbv | 81.17 | | 3.7 |
44 | FA10 | Coagulation factor X | P00742 | | t87 | FACTOR XA INHIBITOR COMPLEX | 1g2l | 71.73 | | 57. |
45 | FA10 | Coagulation factor X | P00742 | | rr8 | Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor | 2xbx | 79.27 | | 15. |
46 | FA10 | Coagulation factor X | P00742 | | rpr | CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR128515 | 1ezq | 76.72 | | 0.9 |
47 | FA10 | Coagulation factor X | P00742 | | rdr | CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208944 | 1nfx | 74.18 | | 3. |
48 | FA10 | Coagulation factor X | P00742 | | oyj | Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor | 2xc5 | 79.78 | | no data |
49 | FA10 | Coagulation factor X | P00742 | | mbm | X-ray crystal structure of human fxa in complex with (S)-N-((2-METHYLBENZOFURAN-5-YLAMINO)(2-OXO-1-(2-OXO-2- (PYRROLIDIN-1-YL)ETHYL)AZEPAN-3- YLAMINO)METHYLENE)NICOTINAMIDE | 3k9x | 71.68 | | 4. |
50 | FA10 | Coagulation factor X | P00742 | | lzi | Aminopyrrolidine Factor Xa inhibitor | 2vwm | 74.43 | | 93. |
51 | FA10 | Coagulation factor X | P00742 | | lzh | Aminopyrrolidine Factor Xa inhibitor | 2vwl | 81.39 | | 95. |
52 | FA10 | Coagulation factor X | P00742 | | lzf | Aminopyrrolidine Factor Xa inhibitor | 2vvc | 80.66 | | 3. |
53 | FA10 | Coagulation factor X | P00742 | | lgm | Factor xa in complex with the inhibitor 3-methyl-1-(3-(5- oxo-4,5-dihydro-1h-1,2,4-triazol-3-yl)phenyl)-6-(2'- (pyrrolidin-1-ylmethyl)biphenyl-4-yl)-5,6-dihydro-1h- pyrazolo[3,4-c]pyridin-7(4h)-one | 3kqe | 73.08 | | 8.1 |
54 | FA10 | Coagulation factor X | P00742 | | lgl | Factor xa in complex with the inhibitor 1-(3-(5-oxo-4,5- dihydro-1h-1,2,4-triazol-3-yl)phenyl)-6-(2'-(pyrrolidin-1- ylmethyl)biphenyl-4-yl)-3-(trifluoromethyl)-5,6-dihydro- 1h-pyrazolo[3,4-c]pyridin-7(4h)-one | 3kqd | 74.46 | | 0.4 |
55 | FA10 | Coagulation factor X | P00742 | | lg0 | FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(4-methoxyphenyl)-6-(4-(1-(pyrrolidin-1-ylmethyl)cyclopropyl)phenyl)-3-(trifluoromethyl)-5,6-dihydro-1H-pyrazolo[3,4-c]pyridin-7(4H)-one | 3cs7 | 74.5 | | 0.021 |
56 | FA10 | Coagulation factor X | P00742 | | l1d | Crystal Structure of FXa in complex with 4,4-disubstituted pyrrolidine-1,2-dicarboxamide inhibitor 1 | 2w3k | 77.27 | | 0.08 |
57 | FA10 | Coagulation factor X | P00742 | | l1c | Crystal Structure of FXa in complex with 4,4-disubstituted pyrrolidine-1,2-dicarboxamide inhibitor 2 | 2w3i | 77.94 | | 0.1 |
58 | FA10 | Coagulation factor X | P00742 | | jnj | X-ray Structure of FXa in complex with 7-fluoroindazole | 2ra0 | 74.51 | | 15.9 |
59 | FA10 | Coagulation factor X | P00742 | | ivk | Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor | 2xc4 | 79.78 | | 9. |
60 | FA10 | Coagulation factor X | P00742 | | ik8 | Factor XA in complex with the inhibitor 1-(3'-amino-1,2-benzisoxazol-5'-yl)-n-(4-(2'-((dimethylamino)methyl)-1h-imidazol-1-yl)-2-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazole-5-carboxamide (razaxaban; DPC906; BMS-561389) | 1z6e | 76.66 | | 0.19 |
61 | FA10 | Coagulation factor X | P00742 | | iib | Crystal structure of factor Xa in complex with 21 | 2bq6 | 79.84 | | 0.07 |
62 | FA10 | Coagulation factor X | P00742 | | iia | Crystal structure of factor Xa in complex with compound ""1"" | 2boh | 80.43 | | 3. |
63 | FA10 | Coagulation factor X | P00742 | | i1h | Crystal structure of factor Xa in complex with 50 | 2bmg | 76.88 | | 18. |
64 | FA10 | Coagulation factor X | P00742 | | gsx | CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX | 2j95 | 77.89 | | 4. |
65 | FA10 | Coagulation factor X | P00742 | | gsj | CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX | 2j4i | 72.04 | | 1. |
66 | FA10 | Coagulation factor X | P00742 | | gsi | Structure and property based design of factor Xa inhibitors:biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs | 2vh0 | 73.74 | | 3.1 |
67 | FA10 | Coagulation factor X | P00742 | | g15 | CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX | 2j94 | 78.11 | | 534. |
68 | FA10 | Coagulation factor X | P00742 | | fxi | The discovery of glycine and related amino acid-based factor xa inhibitors | 2q1j | 75.05 | | 0.8 |
69 | FA10 | Coagulation factor X | P00742 | | fi1 | X-ray crystal structure of human FXA in complex with 6-chloro-N-((3S)-2-oxo-1-(2-oxo-2-((5S)-8-oxo-5,6-dihydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-3(2H,4H,8H)-yl)ethyl)piperidin-3-yl)naphthalene-2-sulfonamide | 3sw2 | 72.29 | | 4.71 |
70 | FA10 | Coagulation factor X | P00742 | | ffg | Factor XA in complex with the inhibitor (R)-6-(2'-((3- HYDROXYPYRROLIDIN-1-YL)METHYL)BIPHENYL-4-YL)-1-(3-(5-OXO-4,5-DIHYDRO-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN- 7(4H)-ONE | 3ffg | 71.98 | | 0.84 |
71 | FA10 | Coagulation factor X | P00742 | | ens | Crystal structure of human FXA in complex with methyl (2Z)-3-[(3-chloro-1H-indol-7-yl)amino]-2-cyano-3-{[(3S)-2-oxo-1-(2-oxo-2-pyrrolidin-1-ylethyl)azepan-3-yl]amino}acrylate | 3ens | 75.94 | | 8.9 |
72 | FA10 | Coagulation factor X | P00742 | | dt8 | FACTOR XA IN COMPLEX WITH THE INHIBITOR (1S,2R,4S)-N1-[(5-chloroindol-2-yl)carbonyl]-4-(N,N-dimethylcarbamoyl)-N2-[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]-1,2-cyclohexanediamine | 2ei8 | 67.02 | | no data |
73 | FA10 | Coagulation factor X | P00742 | | d91 | Factor Xa in complex with the inhibitor 4-[(5-chloroindol-2-yl)sulfonyl]-2-(2-methylpropyl)-1-[[5-(pyridin-4-yl) pyrimidin-2-yl]carbonyl]piperazine | 1wu1 | 79.31 | | 18. |
74 | FA10 | Coagulation factor X | P00742 | | d76 | Factor Xa in complex with the inhibitor 1-[6-methyl-4,5,6,7-tetrahydrothiazolo(5,4-c)pyridin-2-yl] carbonyl-2-carbamoyl-4-(6-chloronaphth-2-ylsulphonyl)piperazine | 1v3x | 76.38 | | 24. |
75 | FA10 | Coagulation factor X | P00742 | | d1q | Factor Xa in complex with D102-4380 | 3tk5 | 76.44 | | no data |
76 | FA10 | Coagulation factor X | P00742 | | d14 | Factor XA in complex with a cis-1,2-diaminocyclohexane derivative | 3iit | 73.73 | | 9.5 |
77 | FA10 | Coagulation factor X | P00742 | | 993 | Crystal structure of human factor XA complexed with 3-Chloro-4-(2-methylamino-imidazol-1-ylmethyl)-thiophene-2-carboxylic acid [4-chloro-2-(5-chloro-pyridin-2-ylcarbamoyl)-6-methoxy-phenyl]-amide | 2p3t | 74.47 | | no data |
78 | FA10 | Coagulation factor X | P00742 | | 663 | Crystal structure of human factor XA complexed with 3-chloro-N-(4-chloro-2-{[(5-chloropyridin-2-yl)amino]carbonyl}-6-methoxyphenyl)-4-[(1-methyl-1H-imidazol-2-yl)methyl]thiophene-2-carboxamide {Pfizer 320663} | 2p3u | 78.44 | | no data |
79 | FA10 | Coagulation factor X | P00742 | | 63c | Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor | 2xby | 78.69 | | no data |
80 | FA10 | Coagulation factor X | P00742 | | 5qc | Factor Xa in complex with the inhibitor 1-(3-amino-1,2-benzisoxazol-5-yl)-6-(2'-(((3r)-3-hydroxy-1-pyrrolidinyl)methyl)-4-biphenylyl)-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7h-pyrazolo[3,4-c]pyridin-7-one | 2fzz | 71.33 | | 0.03 |
81 | FA10 | Coagulation factor X | P00742 | | 4qc | Factor Xa in complex with the inhibitor 3-(6-(2'-((dimethylamino)methyl)-4-biphenylyl)-7-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-1-yl)benzamide | 2g00 | 75.71 | | 0.18 |
82 | FA10 | Coagulation factor X | P00742 | | 4o4 | Factor Xa complex with GTC000006 | 4zh8 | 71.72 | | no data |
83 | FA10 | Coagulation factor X | P00742 | | 4o1 | Factor Xa complex with GTC000401 | 4y76 | 70.08 | | no data |
84 | FA10 | Coagulation factor X | P00742 | | 48w | Factor Xa complex with GTC000398 | 4y71 | 76.57 | | no data |
85 | FA10 | Coagulation factor X | P00742 | | 455 | Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor | 2xbw | 82 | | 10. |
86 | FA10 | Coagulation factor X | P00742 | | 44i | Factor Xa complex with GTC000441 | 4y7b | 71.36 | | no data |
87 | FA10 | Coagulation factor X | P00742 | | 237 | Factor XA inhibitor | 2pr3 | 73.3 | | no data |
88 | FA10 | Coagulation factor X | P00742 | | 815 | CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208815 | 1f0r | 74.19 | | 22. |
89 | FA10 | Coagulation factor X | P00742 | | pr2 | Crystal Structure of Human Coagulation Factor XA Complexed with RPR208707 | 1f0s | 76.4 | | 18. |
90 | FA10 | Coagulation factor X | P00742 | | dx9 | COAGULATION FACTOR XA INHIBITOR COMPLEX | 1fax | 73.16 | | 41. |
91 | FA10 | Coagulation factor X | P00742 | | xmj | Human coagulation factor Xa in complex with M54476 | 1iql | 76.82 | | no data |
92 | FA10 | Coagulation factor X | P00742 | | xmk | Human coagulation factor Xa in complex with M54471 | 1iqm | 74.09 | | no data |
93 | FA10 | Coagulation factor X | P00742 | | fxv | Crystal Structure of Human Coagulation Factor XA Complexed with FXV673 | 1ksn | 79.5 | | 0.4 |
94 | FA10 | Coagulation factor X | P00742 | | rrp | CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR132747 | 1nfu | 75.23 | | 18. |
95 | FA10 | Coagulation factor X | P00742 | | rrr | CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR209685 | 1nfw | 80.25 | | 1.1 |
96 | FA10 | Coagulation factor X | P00742 | | rtr | CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR200095 | 1nfy | 79.85 | | 1.3 |
97 | FA10 | Coagulation factor X | P00742 | | 4pp | FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A,(2S)-(3'-AMIDINO-3-BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID | 1xkb | 77 | | no data |
98 | FA10 | Coagulation factor X | P00742 | | 4pp | FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A,(2S)-(3'-AMIDINO-3-BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID | 1xka | 78.27 | | 131. |
99 | FA10 | Coagulation factor X | P00742 | | 784 | Factor Xa - cation | 2bok | 80.76 | | 280. |
100 | FA10 | Coagulation factor X | P00742 | | iid | Crystal structure of factor Xa in complex with 43 | 2bq7 | 78.37 | | 89. |
101 | FA10 | Coagulation factor X | P00742 | | iie | CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH COMPOUND 45 | 2bqw | 79.83 | | 3. |
102 | FA10 | Coagulation factor X | P00742 | | gsk | Crystal structure of a Human Factor Xa inhibitor complex | 2cji | 78.4 | | 6. |
103 | FA10 | Coagulation factor X | P00742 | | d01 | Factor Xa in complex with the inhibitor 2-[[4-[(5-chloroindol-2-yl)sulfonyl]piperazin-1-yl] carbonyl]thieno[3,2-b]pyridine n-oxide | 2d1j | 78.79 | | no data |
104 | FA10 | Coagulation factor X | P00742 | | d92 | FACTOR XA IN COMPLEX WITH THE INHIBITOR (-)-cis-N1-[(5-Chloroindol-2-yl)carbonyl]-N2-[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]-1,2-cyclohexanediamine | 2ei6 | 74.42 | | 41. |
105 | FA10 | Coagulation factor X | P00742 | | d93 | FACTOR XA IN COMPLEX WITH THE INHIBITOR trans-N1-[(5-Chloroindol-2-yl)carbonyl]-N2-[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]-1,2-cyclohexanediamine | 2ei7 | 78.87 | | no data |
106 | FA10 | Coagulation factor X | P00742 | | gsq | CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX | 2j2u | 78.73 | | 47. |
107 | FA10 | Coagulation factor X | P00742 | | gs6 | CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX | 2j34 | 77.84 | | 15. |
108 | FA10 | Coagulation factor X | P00742 | | gs5 | CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX | 2j38 | 77.47 | | no data |
109 | FA10 | Coagulation factor X | P00742 | | 701 | Selective and Dual Action Orally Active Inhibitors of Thrombin and Factor Xa | 2uwo | 80.09 | | 2. |
110 | FA10 | Coagulation factor X | P00742 | | 895 | Selective and Dual Action Orally Active Inhibitors of Thrombin and Factor Xa | 2uwl | 77.59 | | 4. |
111 | FA10 | Coagulation factor X | P00742 | | 894 | Factor Xa inhibitor complex | 2uwp | 78.06 | | 154. |
112 | FA10 | Coagulation factor X | P00742 | | bi7 | Factor Xa - cation inhibitor complex | 2jkh | 76.56 | | 9. |
113 | FA10 | Coagulation factor X | P00742 | | gg2 | Factor Xa in Complex with the Inhibitor APIXABAN (BMS-562247) AKA 1-(4-METHOXYPHENYL)-7-OXO-6-(4-(2-OXO-1-PIPERIDINYL)PHENYL)-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3, 4-C]PYRIDINE-3-CARBOXAMIDE | 2p16 | 78.83 | | 0.08 |
114 | FA10 | Coagulation factor X | P00742 | | me1 | Factor xa in complex with the inhibitor 5-chloro-N-(2-(4-(2-oxopyridin-1(2H)-yl)benzamido)ethyl)thiophene-2-carboxamide | 2p93 | 79.25 | | 1.5 |
115 | FA10 | Coagulation factor X | P00742 | | me4 | Factor xa in complex with the inhibitor 3-chloro-N-((1R,2S)-2-(4-(2-oxopyridin-1(2H)-yl)benzamido)cyclohexyl)-1H-indole-6-carboxamide | 2p94 | 75.27 | | 0.67 |
116 | FA10 | Coagulation factor X | P00742 | | me5 | Factor xa in complex with the inhibitor 5-chloro-N-((1R,2S)-2-(4-(2-oxopyridin-1(2H)-YL)benzamido) cyclopentyl)thiophene-2-carboxamide | 2p95 | 81.51 | | 0.43 |
117 | FA10 | Coagulation factor X | P00742 | | 230 | An Orally Efficacious Factor Xa Inhibitor | 2phb | 77.12 | | 0.32 |
118 | FA10 | Coagulation factor X | P00742 | | h22 | Aminopyrrolidine Factor Xa inhibitor | 2vvu | 78.74 | | 8. |
119 | FA10 | Coagulation factor X | P00742 | | h21 | Aminopyrrolidine-related triazole Factor Xa inhibitor | 2vvv | 79.62 | | 6. |
120 | FA10 | Coagulation factor X | P00742 | | h25 | Aminopyrrolidine Factor Xa inhibitor | 2vwn | 82.91 | | 10. |
121 | FA10 | Coagulation factor X | P00742 | | lzg | Aminopyrrolidine Factor Xa inhibitor | 2vwo | 82.33 | | 31. |
122 | FA10 | Coagulation factor X | P00742 | | 461 | Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs | 2wyg | 74.84 | | 2. |
123 | FA10 | Coagulation factor X | P00742 | | 898 | Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs | 2wyj | 75.46 | | 1. |
124 | FA10 | Coagulation factor X | P00742 | | fjd | FACTOR XA - CATION INHIBITOR COMPLEX | 2y5g | 79.06 | | 146. |
125 | FA10 | Coagulation factor X | P00742 | | y5h | FACTOR XA - CATION INHIBITOR COMPLEX | 2y5h | 76.82 | | 1620. |
126 | FA10 | Coagulation factor X | P00742 | | yet | Crystal structure of human FxA in complex with (S)-2-cyano-1-(2-methylbenzofuran-5-yl)-3-(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-yl)guanidine | 3hpt | 77.94 | | 6.5 |
127 | FA10 | Coagulation factor X | P00742 | | 443 | Discovery of Tetrahydropyrimidin-2(1H)-one derivative TAK-442: A potent, selective and orally active factor Xa inhibitor | 3kl6 | 84.52 | | 3.5 |
128 | FA10 | Coagulation factor X | P00742 | | d90 | Factor Xa in complex with a phenylenediamine derivative | 3q3k | 80.32 | | 7.4 |
129 | FA10 | Coagulation factor X | P00742 | | d46 | factor Xa in complex with D46-5241 | 3tk6 | 81.77 | | no data |
130 | FA10 | Coagulation factor X | P00742 | | a7i | Factor Xa in complex with a potent 2-amino-ethane sulfonamide inhibitor | 4a7i | 83.1 | | 2. |
131 | FA10 | Coagulation factor X | P00742 | | 48u | Factor Xa complex with GTC000101 | 4y6d | 79.33 | | no data |
132 | FA10 | Coagulation factor X | P00742 | | 4o6 | Factor Xa complex with GTC000406 | 4y79 | 78.17 | | 11. |
133 | FA10 | Coagulation factor X | P00742 | | 987 | Factor Xa complex with GTC000422 | 4y7a | 77.33 | | no data |
134 | FA10 | Coagulation factor X | P00742 | | 4o5 | Factor Xa complex with GTC000102 | 4zha | 79.75 | | no data |
135 | FA10 | Coagulation factor X | P00742 | | riv | Factor Xa in complex with BAY59-7939 | 2w26 | 81.62 | | 0.4 |
136 | FA10 | Coagulation factor X | P00742 | | riv | DesGla-XaS195A Bound to Aptamer 11F7t and Rivaroxaban | 5vof | 81.09 | | no data |
137 | FA11 | Coagulation factor XI | P03951 | | xj8 | Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design | 4cra | 76.17 | | 60. |
138 | FA11 | Coagulation factor XI | P03951 | | r9b | Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design | 4crf | 84.55 | | 0.5 |
139 | FA11 | Coagulation factor XI | P03951 | | nrj | FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(5E,8S)-8-[(6R)-6-(3-chlorophenyl)-2-oxo-1,3-oxazinan-3-yl]-2-oxo-1,3,4,7,8,10-hexahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate | 5qqo | 86.94 | | no data |
140 | FA11 | Coagulation factor XI | P03951 | | nr7 | FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(5E,8S)-8-[(4S)-4-(3-chlorophenyl)-2-oxopiperidin-1-yl]-2-oxo-1,3,4,7,8,10-hexahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate | 5qqp | 75.07 | | no data |
141 | FA11 | Coagulation factor XI | P03951 | | j1j | Human FXIa in complex with small molecule inhibitors. | 4d76 | 82.96 | | no data |
142 | FA11 | Coagulation factor XI | P03951 | | ixa | Human FXIa in complex with small molecule inhibitors. | 4d7f | 80.13 | | no data |
143 | FA11 | Coagulation factor XI | P03951 | | e6u | Human FXIa in complex with small molecule inhibitors. | 4d7g | 86.17 | | no data |
144 | FA11 | Coagulation factor XI | P03951 | | bvj | FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl ~{N}-[4-[[(1~{S})-2-[(~{E})-3-[3-chloranyl-2-fluoranyl-6-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-3,4-dihydro-1~{H}-isoquinolin-1-yl]carbonylamino]phenyl]carbamate | 5qcm | 77.76 | | 110. |
145 | FA11 | Coagulation factor XI | P03951 | | buy | FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(1~{S})-2-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-3,4-dihydro-1~{H}-isoquinolin-1-yl]carbonylamino]benzoic acid | 5qcl | 77.92 | | 11. |
146 | FA11 | Coagulation factor XI | P03951 | | buv | FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(2~{S},3~{R})-1-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-3-phenyl-pyrrolidin-2-yl]carbonylamino]benzoic acid | 5qck | 76.7 | | 23. |
147 | FA11 | Coagulation factor XI | P03951 | | 7p0 | FACTOR XIA IN COMPLEX WITH THE INHIBITOR N-[(1S)-1-benzyl-2-[2-[5-chloro-2-(tetrazol-1-yl)phenyl]ethylamino]-2-oxo-ethyl]-4-hydroxy-2-oxo-1H-quinoline-6-carboxamide | 5e2p | 84.15 | | 1.6 |
148 | FA11 | Coagulation factor XI | P03951 | | 7p0 | Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design | 4crb | 84.21 | | 27. |
149 | FA11 | Coagulation factor XI | P03951 | | 716 | Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 2-[2-(3-Chloro-phenyl)-2-hydroxy-acetylamino]-N-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-3-methyl-butyramide | 1zpc | 77.73 | | 254. |
150 | FA11 | Coagulation factor XI | P03951 | | 624 | Factor XI complexed with a pyrimidinone inhibitor | 1zsl | 75.73 | | no data |
151 | FA11 | Coagulation factor XI | P03951 | | 5su | FACTOR XIA (C500S [C122S]) IN COMPLEX WITH THE INHIBITOR methyl ~{N}-[4-[2-[(1~{S})-1-[[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]amino]-2-phenyl-ethyl]pyridin-4-yl]phenyl]carbamate | 5exn | 74.65 | | 23. |
152 | FA11 | Coagulation factor XI | P03951 | | 3y5 | FACTOR XIA IN COMPLEX WITH THE INHIBITOR 1-{(1S)-1-[4-(3-amino-1H-indazol-6-yl)-5-chloro-1H-imidazol-2-yl]-2-phenylethyl}-3-[5-chloro-2-(1H-tetrazol-1-yl)benzyl]urea | 4x6n | 81.91 | | 1.5 |
153 | FA11 | Coagulation factor XI | P03951 | | 3y4 | FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl (4-{4-chloro-2-[(1S)-1-({3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]propanoyl}amino)-2-phenylethyl]-1H-imidazol-5-yl}phenyl)carbamate | 4x6o | 80.97 | | 1.9 |
154 | FA11 | Coagulation factor XI | P03951 | | 3y3 | FACTOR XIA IN COMPLEX WITH THE INHIBITOR 1-{(1S)-1-[4-(3-amino-1H-indazol-6-yl)-5-chloro-1H-imidazol-2-yl]-2-phenylethyl}-3-[2-(aminomethyl)-5-chlorobenzyl]urea | 4x6m | 77.72 | | 5.8 |
155 | FA11 | Coagulation factor XI | P03951 | | 3vm | FACTOR XIA IN COMPLEX WITH THE INHIBITOR trans-N-{(1S)-1-[4-(3-amino-2H-indazol-6-yl)pyridin-2-yl]-2-phenylethyl}-4-(aminomethyl)cyclohexanecarboxamide | 4wxi | 75.23 | | 8.4 |
156 | FA11 | Coagulation factor XI | P03951 | | 39f | Factor XIa in complex with the inhibitor (2S)-6-amino-N-{(1S)-1-[4-(3-amino-2H-indazol-6-yl)-5-chloro-1H-imidazol-2-yl]-2-phenylethyl}-2-ethylhexanamide | 4ty7 | 73.07 | | 0.3 |
157 | FA11 | Coagulation factor XI | P03951 | | 39d | Factor XIa in complex with the inhibitor 4-{2-[(1S)-1-({[trans-4-(aminomethyl)cyclohexyl]carbonyl}amino)-2-phenylethyl]-1H-imidazol-4-yl}benzamide | 4ty6 | 74.54 | | 30. |
158 | FA11 | Coagulation factor XI | P03951 | | 1t6 | Factor XIa in complex with the inhibitor 5-aminocarbonyl-2-[3-[(2s,4r)-6-carbamimidoyl-4-methyl-4-phenyl-2,3-dihydro-1h-quinolin-2-yl]phenyl]benzoic acid | 4na8 | 71.83 | | 1.5 |
159 | FA11 | Coagulation factor XI | P03951 | | 368 | Factor XI catalytic domain complexed with 2-guanidino-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl nicotinate | 1zlr | 73.34 | | no data |
160 | FA11 | Coagulation factor XI | P03951 | | 427 | Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with (R)-1-(4-(4-(hydroxymethyl)-1,3,2-dioxaborolan-2-yl)phenyl)guanidine | 1zmn | 80.66 | | no data |
161 | FA11 | Coagulation factor XI | P03951 | | 5ss | FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-(aminomethyl)-~{N}-[(1~{S})-1-[4-(3-oxidanyl-1~{H}-indazol-5-yl)pyridin-2-yl]-2-phenyl-ethyl]cyclohexane-1-carboxamide | 5exl | 78.14 | | 3.7 |
162 | FA11 | Coagulation factor XI | P03951 | | 5st | FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl ~{N}-[4-[2-[(1~{S})-1-[[4-(aminomethyl)cyclohexyl]carbonylamino]-2-phenyl-ethyl]pyridin-4-yl]phenyl]carbamate | 5exm | 72.51 | | 6.3 |
163 | FA11 | Coagulation factor XI | P03951 | | j4x | Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design | 4crg | 70.32 | | no data |
164 | FA11 | Coagulation factor XI | P03951 | | 421 | Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 6-Carbamimidoyl-4-(3-hydroxy-2-methyl-benzoylamino)-naphthalene-2-carboxylic acid methyl ester | 1zsk | 73.73 | | no data |
165 | FA11 | Coagulation factor XI | P03951 | | 709 | Crystal Structure of the Catalytic Domain of Coagulation Factor XI in complex with N-(7-Carbamimidoyl-naphthalen-1-yl)-3-hydroxy-2-methyl-benzamide | 1zsj | 78.21 | | no data |
166 | FA7 | Coagulation factor VII | P08709 | | gil | crystal structure of factor VII.stf complexed with pd0297121 | 2c4f | 68.78 | | 20. |
167 | FA7 | Coagulation factor VII | P08709 | | 9s1 | Crystal Structure of Factor VIIa in complex with 1-[[3-[4-(5-amino-1H-pyrrolo[3,2-b]pyridin-2-yl)-5-hydroxypyrazol-1-yl]phenyl]methyl]-3-phenylurea | 5pb3 | 74.14 | | no data |
168 | FA7 | Coagulation factor VII | P08709 | | 905 | Short Factor VIIa with a small molecule inhibitor | 1ygc | 75.99 | | no data |
169 | FA7 | Coagulation factor VII | P08709 | | 82j | Factor VIIa in complex with the inhibitor 3-{[(2R)-17-ethyl-4-methyl-3,12-dioxo-7-[(propan-2-yl)sulfonyl]-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaen-2-yl]amino}benzamide | 5u6j | 78.31 | | 23. |
170 | FA7 | Coagulation factor VII | P08709 | | 7zj | Crystal Structure of Factor VIIa in complex with N-(2-amino-1H-benzimidazol-5-yl)-2-[3-[(2-amino-2-oxoethyl)-methylsulfonylamino]phenyl]acetamide;2,2,2-trifluoroacetic acid | 5pau | 76.91 | | no data |
171 | FA7 | Coagulation factor VII | P08709 | | 7za | Crystal Structure of Factor VIIa in complex with 2-[(1-aminoisoquinolin-6-yl)amino]-2-(3-ethoxy-4-propan-2-yloxyphenyl)-1-(2-phenylpyrrolidin-1-yl)ethanone | 5paq | 74.68 | | no data |
172 | FA7 | Coagulation factor VII | P08709 | | 7z1 | Crystal Structure of Factor VIIa in complex with 2-[(1-aminoisoquinolin-6-yl)amino]-2-(5-ethoxy-2-fluorophenyl)-1-(2-phenylpyrrolidin-1-yl)ethanone | 5pam | 76.19 | | no data |
173 | FA7 | Coagulation factor VII | P08709 | | 7yp | Crystal Structure of Factor VIIa in complex with N-[[4-(aminomethyl)-2-(2-amino-2-oxoethoxy)phenyl]methyl]-2-(4-hydroxyphenyl)-2-methoxyacetamide;hydrochloride | 5pak | 74.79 | | no data |
174 | FA7 | Coagulation factor VII | P08709 | | 7ym | human factor VIIa in complex with N-(2-amino-1H-benzimidazol-5-yl)-1-[3-[[(3,5-dimethyl-1,2-oxazol-4-yl)carbamoylamino]methyl]phenyl]-5-hydroxypyrazole-4-carboxamide at 1.73A | 5pai | 72.64 | | no data |
175 | FA7 | Coagulation factor VII | P08709 | | 7xd | Crystal Structure of Factor VIIa in complex with 1-[[3-[2-hydroxy-3-(1H-pyrrolo[3,2-c]pyridin-2-yl)phenyl]phenyl]methyl]-3-phenylurea | 5pab | 74.38 | | no data |
176 | FA7 | Coagulation factor VII | P08709 | | 7lr | Crystal Structure of Factor VIIa in complex with N-(2-amino-1H-benzimidazol-5-yl)-2-[3-[(2-amino-2-oxoethyl)-methylsulfonylamino]-5-chlorophenyl]acetamide;2,2,2-trifluoroacetic acid | 5paf | 78.64 | | no data |
177 | FA7 | Coagulation factor VII | P08709 | | 7ks | Factor VIIa in complex with the inhibitor (5R,11R)-11-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-16-(cyclopropylsulfonyl)-7-(2,2-difluoroethoxy)-5,13-dimethyl-2,13-diazatricyclo[13.3.1.1~6,10~]icosa-1(19),6(20),7,9,15,17-hexaene-3,12-dione | 5tqg | 78.85 | | 0.24 |
178 | FA7 | Coagulation factor VII | P08709 | | 7kr | Factor VIIa in complex with the inhibitor (11R)-11-[(1-aminoisoquinolin-6-yl)amino]-16-(cyclopropylsulfonyl)-13-methyl-2,13-diazatricyclo[13.3.1.1~6,10~]icosa-1(19),6(20),7,9,15,17-hexaene-3,12-dione | 5tqf | 80.14 | | 5. |
179 | FA7 | Coagulation factor VII | P08709 | | 7kq | Factor VIIa in complex with the inhibitor (5R)-5-[(1-aminoisoquinolin-6-yl)amino]-19-(cyclopropylsulfonyl)-3-methyl-13-oxa-3,15-diazatricyclo[14.3.1.1~6,10~]henicosa-1(20),6(21),7,9,16,18-hexaene-4,14-dione | 5tqe | 80.2 | | 190. |
180 | FA7 | Coagulation factor VII | P08709 | | 70d | Factor VIIa in complex with the inhibitor 1-[(2R,15R)-2-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-4,15,20-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6,8,10(21),16,19-hexaen-7-yl] cyclobutane-1-carboxylic acid | 5l2y | 76.52 | | 0.14 |
181 | FA7 | Coagulation factor VII | P08709 | | 70a | Factor VIIa in complex with the inhibitor (2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,15,17-trimethyl-7-[1-(1H-tetrazol-5-yl)cyclopropyl]-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione | 5l30 | 75.37 | | 0.72 |
182 | FA7 | Coagulation factor VII | P08709 | | 67o | Factor VIIA in complex with the inhibitor (2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-8-fluoro-7-hydroxy-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione | 5i46 | 80.18 | | no data |
183 | FA7 | Coagulation factor VII | P08709 | | 4t0 | FACTOR VIIA IN COMPLEX WITH THE INHIBITOR N-{3-[(2R)-1-{(2R)-2-[(1-aminoisoquinolin-6-yl)amino]-2-phenylacetyl}pyrrolidin-2-yl]-4-(propan-2-ylsulfonyl)phenyl}acetamide | 4zxx | 77.84 | | 8. |
184 | FA7 | Coagulation factor VII | P08709 | | 4k1 | Factor VIIa in complex with the inhibitor 2-(2-{(R)-[(4-carbamimidoylphenyl)amino][5-ethoxy-2-fluoro-3-(propan-2-yloxy)phenyl]methyl}-1H-imidazol-4-yl)benzamide | 4yt7 | 76.85 | | 1.7 |
185 | FA7 | Coagulation factor VII | P08709 | | 413 | Factor7 - 413 complex | 1w7x | 73.06 | | 4. |
186 | FA7 | Coagulation factor VII | P08709 | | 413 | Factor7 - 413 complex | 1w8b | 65.82 | | no data |
187 | FA7 | Coagulation factor VII | P08709 | | 2kf | Factor viia in complex with the inhibitor (2R)-2-[(1-aminoisoquinolin-6-yl)amino]-2-[3-ethoxy-4-(propan-2-yloxy)phenyl]-N-[2-(propan-2-ylsulfonyl)benzyl]ethanamide | 4nga | 80.42 | | 17. |
188 | FA7 | Coagulation factor VII | P08709 | | 2ke | Factor viia in complex with the inhibitor (2R)-2-[(1-aminoisoquinolin-6-yl)amino]-2-[3-ethoxy-4-(propan-2-yloxy)phenyl]-n-(3-sulfamoylbenzyl)ethanamide | 4ng9 | 77.25 | | 75. |
189 | FA7 | Coagulation factor VII | P08709 | | 24x | Crystal structure analysis of human Factor VIIa , Souluble tissue factor complexed with BCX-3607 | 2ec9 | 67.74 | | no data |
190 | FA7 | Coagulation factor VII | P08709 | | 1t7 | Factor VIIa in complex with the inhibitor 3'-amino-5'-[(2s,4r)-6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydroquinolin-2-yl]biphenyl-2-carboxylic acid | 4na9 | 70.83 | | 41. |
191 | FA7 | Coagulation factor VII | P08709 | | 1ok | Structure of factor VIIA in complex with the inhibitor (2R)-2-[(1-AMINOISOQUINOLIN-6-YL)AMINO]-2-[3-ETHOXY-4-(PROPAN-2-YLOXY)PHENYL]-N-(PHENYLSULFONYL)ETHANAMIDE | 4jyu | 76.07 | | 10. |
192 | FA7 | Coagulation factor VII | P08709 | | 1oj | Structure of factor VIIA in complex with the inhibitor (2R)-2-[3-ETHOXY-4-(PROPAN-2-YLOXY)PHENYL]-2-(ISOQUINOLIN-6-YLAMINO)-N-[(3-SULFAMOYLPHENYL)SULFONYL]ETHANAMIDE | 4jyv | 74.16 | | 17. |
193 | FA7 | Coagulation factor VII | P08709 | | 03r | Crystal structure of a ternary complex of factor VIIa/tissue factor and 2-[[6-[3-(aminoiminomethyl)phenoxy]-3,5-difluro-4-[(1-methyl-3-phenylpropyl)amino]-2-pyridinyl]oxy]-benzoic acid | 2aei | 71.98 | | 86. |
194 | FA7 | Coagulation factor VII | P08709 | | cr9 | Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala190 Protease (Ala190 uPA) | 1o5d | 76.46 | | no data |
195 | FA7 | Coagulation factor VII | P08709 | | 380 | tf7a_4380 complex | 1w2k | 77.89 | | 350. |
196 | FA7 | Coagulation factor VII | P08709 | | 346 | Orally available Factor7a inhibitor | 2bz6 | 73.97 | | 81. |
197 | FA7 | Coagulation factor VII | P08709 | | 7nh | Novel 5-Azaindole Factor VIIa Inhibitors | 2flr | 80.61 | | 800. |
198 | FA7 | Coagulation factor VII | P08709 | | 1gg | Structure of FACTOR VIIA in complex with the inhibitor (6S)-N-(4-CARBAMIMIDOYLBENZYL)-1-CHLORO-3-(CYCLOBUTYLAMINO)-8,8-DIETHYL-4-OXO-4,6,7,8-TETRAHYDROPYRROLO[1,2-A]PYRAZINE-6-CARBOXAMIDE | 4isi | 75.81 | | 7.3 |
199 | FA7 | Coagulation factor VII | P08709 | | 4jy | Factor VIIa in complex with the inhibitor 4-{[(R)-[5-ethoxy-2-fluoro-3-(propan-2-yloxy)phenyl](4-phenyl-1H-imidazol-2-yl)methyl]amino}benzenecarboximidamide | 4yt6 | 76.55 | | 11. |
200 | FA7 | Coagulation factor VII | P08709 | | 4t1 | FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (2R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione | 4zxy | 76.47 | | 400. |
201 | FA7 | Coagulation factor VII | P08709 | | 7y7 | human factor VIIa in complex with 5-hydroxy-N-(4-oxo-3H-quinazolin-6-yl)-1-[3-[(phenylcarbamoylamino)methyl]phenyl]pyrazole-4-carboxamide at 1.50A | 5pac | 73.71 | | no data |
202 | FA7 | Coagulation factor VII | P08709 | | 7ya | Crystal Structure of Factor VIIa in complex with (2S)-2-hydroxy-N-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]propanamide | 5pae | 69.88 | | no data |
203 | FA7 | Coagulation factor VII | P08709 | | 7yj | Crystal Structure of Factor VIIa in complex with (2R)-2-hydroxy-N-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]-3-methylbutanamide;hydrobromide | 5pag | 65.34 | | no data |
204 | FA7 | Coagulation factor VII | P08709 | | 7xj | Crystal Structure of Factor VIIa in complex with 1-(1-aminoisoquinolin-6-yl)-3-benzylurea | 5paj | 82.73 | | no data |
205 | FA7 | Coagulation factor VII | P08709 | | 7z4 | Crystal Structure of Factor VIIa in complex with 5-hydroxy-N-(3-oxo-1,2-dihydroisoindol-5-yl)-1-[3-[(phenylcarbamoylamino)methyl]phenyl]pyrazole-4-carboxamide | 5pan | 73.94 | | no data |
206 | FA7 | Coagulation factor VII | P08709 | | 7z7 | Crystal Structure of Factor VIIa in complex with (2S)-2,3-dihydroxy-N-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]propanamide;hydrobromide | 5pao | 72.22 | | no data |
207 | FA7 | Coagulation factor VII | P08709 | | 7zd | Crystal Structure of Factor VIIa in complex with (2S)-2-hydroxy-N-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]-3-phenylpropanamide | 5pas | 79.67 | | no data |
208 | FA7 | Coagulation factor VII | P08709 | | 7zg | Crystal Structure of Factor VIIa in complex with N-(2-amino-1H-benzimidazol-5-yl)-2-(3-chlorophenyl)acetamide | 5pat | 82.09 | | no data |
209 | FA7 | Coagulation factor VII | P08709 | | 7zm | Crystal Structure of Factor VIIa in complex with N-(6-aminopyridin-3-yl)-5-hydroxy-1-phenylpyrazole-4-carboxamide | 5pav | 87.22 | | no data |
210 | FA7 | Coagulation factor VII | P08709 | | 7zp | Crystal Structure of Factor VIIa in complex with 1-(2,6-difluorophenyl)-3-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]urea | 5pax | 70.36 | | no data |
211 | FA7 | Coagulation factor VII | P08709 | | 7zy | Crystal Structure of Factor VIIa in complex with 1-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]-3-phenylurea | 5pay | 72.07 | | no data |
212 | FA7 | Coagulation factor VII | P08709 | | 7lx | Crystal Structure of Factor VIIa in complex with 2-(4-ethoxy-3-methoxyphenyl)-2-(isoquinolin-6-ylamino)acetic acid | 5pb0 | 79.32 | | no data |
213 | FA7 | Coagulation factor VII | P08709 | | 9rs | human factor VIIa in complex with 1-[[3-[5-hydroxy-3-methyl-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]-3-phenylurea at 2.43A | 5pb4 | 72.42 | | no data |
214 | FA7 | Coagulation factor VII | P08709 | | 9ry | human factor VIIa in complex with 1-[[3-[5-hydroxy-4-(7H-pyrrolo[2,3-d]pyrimidin-6-yl)pyrazol-1-yl]phenyl]methyl]-3-phenylurea at 1.84A | 5pb5 | 71.34 | | no data |
215 | FA7 | Coagulation factor VII | P08709 | | 9rv | Crystal Structure of Factor VIIa in complex with N-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]pentanamide | 5pb6 | 68.35 | | no data |
216 | FA9 | Coagulation factor IX | P00740 | | 5ny | Development of a novel tricyclic class of potent and selective FIXa inhibitors | 5egm | 73.52 | | 2.4 |
217 | FA9 | Coagulation factor IX | P00740 | | 4m1 | Development of a novel class of potent and selective FIXa inhibitors | 4zae | 75 | | 3.6 |
218 | FA9 | Coagulation factor IX | P00740 | | izx | Selective Benzothiophine Inhibitors of Factor IXa | 3lc5 | 79.09 | | 270. |
219 | FA9 | Coagulation factor IX | P00740 | | 4ln | Rapid development of two Factor IXa inhibitors from Hit to Lead | 4z0k | 75.92 | | 462. |
220 | FA9 | Coagulation factor IX | P00740 | | 7gq | Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors | 5tnt | 73.98 | | 4.9 |
221 | FA9 | Coagulation factor IX | P00740 | | 4k6 | Rapid development of two Factor IXa inhibitors from Hit to Lead | 4yzu | 75.02 | | 9000. |
222 | HEPS | Serine protease hepsin | P05981 | TMPRSS1 | cr9 | Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala190 Protease (Ala190 uPA) | 1o5f | 72.4 | | 850. |
223 | HEPS | Serine protease hepsin | P05981 | TMPRSS1 | 50k | Crystal Structure of Serine protease Hepsin in complex with Inhibitor | 5ce1 | 78.49 | | no data |
224 | KLK5 | Kallikrein-5 | Q9Y337 | SCTE | j08 | Crystal Structure of Human Kallikrein 5 in complex with GSK144 | 6qfe | 92.71 | | no data |
225 | KLK6 | Kallikrein-6 | Q92876 | PRSS18 PRSS9 | rh5 | Crystal Structure of Human Kallikrein 6 (N217D/I218Y/K224R) in complex with GSK3496783A | 6skb | 89.55 | | no data |
226 | KLK6 | Kallikrein-6 | Q92876 | PRSS18 PRSS9 | lh8 | Crystal Structure of Human Kallikrein 6 (I218Y) in complex with GSK3448330A | 6skc | 80.57 | | no data |
227 | KLK6 | Kallikrein-6 | Q92876 | PRSS18 PRSS9 | lh5 | Crystal Structure of Human Kallikrein 6 (N217D/I218Y/K224R) in complex with GSK3496783A | 6skb | 94.33 | | no data |
228 | KLK6 | Kallikrein-6 | Q92876 | PRSS18 PRSS9 | lh2 | Crystal Structure of Human Kallikrein 6 (I218Y) in complex with GSK3397892A | 6skd | 82.89 | | no data |
229 | KLK6 | Kallikrein-6 | Q92876 | PRSS18 PRSS9 | j3b | Crystal Structure of Human Kallikrein 6 in complex with GSK3239861A | 6qh9 | 89.98 | | no data |
230 | KLK6 | Kallikrein-6 | Q92876 | PRSS18 PRSS9 | j2w | Crystal Structure of Human Kallikrein 6 in complex with GSK578724A | 6qhb | 80.29 | | no data |
231 | KLK6 | Kallikrein-6 | Q92876 | PRSS18 PRSS9 | j2q | Crystal Structure of Human Kallikrein 6 in complex with GSK3205388B | 6qha | 81.03 | | no data |
232 | KLK6 | Kallikrein-6 | Q92876 | PRSS18 PRSS9 | j2n | Crystal Structure of Human Kallikrein 6 in complex with GSK3239861A | 6qh9 | 90.47 | | no data |
233 | KLK6 | Kallikrein-6 | Q92876 | PRSS18 PRSS9 | j08 | Crystal Structure of Human Kallikrein 6 (I218Y) in complex with GSK144 | 6qfg | 72.55 | | no data |
234 | KLK6 | Kallikrein-6 | Q92876 | PRSS18 PRSS9 | j08 | Crystal Structure of Human Kallikrein 6 (N217D/I218Y/K224R) in complex with GSK144. | 6qfh | 72.64 | | no data |
235 | KLK6 | Kallikrein-6 | Q92876 | PRSS18 PRSS9 | j08 | Crystal Structure of Human Kallikrein 6 in complex with GSK144 | 6qff | 73.95 | | no data |
236 | KLK6 | Kallikrein-6 | Q92876 | PRSS18 PRSS9 | 135 | Crystal Structure of Human Kallikrein 6 in complex with GSK358180B | 6qhc | 77.72 | | no data |
237 | KLK6 | Kallikrein-6 | Q92876 | PRSS18 PRSS9 | 0hl | Virtual Screening and X-Ray Crystallography for Human Kallikrein 6 Inhibitors with an Amidinothiophene P1 Group | 3vfe | 72.41 | | no data |
238 | KLK6 | Kallikrein-6 | Q92876 | PRSS18 PRSS9 | 0hm | Human Kallikrein 6 Inhibitors with a para-Amidobenzylanmine P1 Group Carry a High Binding Efficiency | 4d8n | 76.23 | | 1800. |
239 | KLK7 | Kallikrein-7 | P49862 | PRSS6 SCCE | 8vx | Human kallikrein 7 in complex with 1,4-diazepane-7-one 1-acetamide derivative | 5yjk | 69.3 | | 820. |
240 | KLK7 | Kallikrein-7 | P49862 | PRSS6 SCCE | 8r3 | Human kallikrein 7 in complex with 1,3,6-trisubstituted 1,4-diazepane-7-one | 5y9l | 74.41 | | 1900. |
241 | KLK7 | Kallikrein-7 | P49862 | PRSS6 SCCE | 5vt | KALLIKREIN-7 IN COMPLEX WITH COMPOUND1 | 5fah | 75.51 | | 700. |
242 | KLKB1 | Plasma kallikrein | P03952 | KLK3 | gbt | Structure of human plasma kallikrein | 5tjx | 83.39 | | 153. |
243 | KLKB1 | Plasma kallikrein | P03952 | KLK3 | 7sd | Full length human plasma kallikrein with inhibitor | 6o1g | 81.78 | | no data |
244 | KLKB1 | Plasma kallikrein | P03952 | KLK3 | 7sd | Structure of human plasma kallikrein protease domain with inhibitor | 6o1s | 85.36 | | no data |
245 | ST14 | Suppressor of tumorigenicity 14 protein | Q9Y5Y6 | PRSS14 SNC19 TADG15 | ntx | Crystal structure of matriptase in complex with inhibitor | 4o97 | 63.21 | | 3. |
246 | ST14 | Suppressor of tumorigenicity 14 protein | Q9Y5Y6 | PRSS14 SNC19 TADG15 | nt4 | Crystal structure of matriptase in complex with inhibitor | 4o9v | 68.01 | | 10. |
247 | ST14 | Suppressor of tumorigenicity 14 protein | Q9Y5Y6 | PRSS14 SNC19 TADG15 | n4c | Crystal Structure of Matriptase in complex with Inhibitor"". | 4jzi | 65.67 | | 40. |
248 | ST14 | Suppressor of tumorigenicity 14 protein | Q9Y5Y6 | PRSS14 SNC19 TADG15 | n4a | Crystal Structure of Matriptase in complex with Inhibitor | 4jyt | 64.34 | | 40. |
249 | ST14 | Suppressor of tumorigenicity 14 protein | Q9Y5Y6 | PRSS14 SNC19 TADG15 | f4d | Crystal Structure of Matriptase in complex with Inhibitor | 4jz1 | 74.84 | | 200. |
250 | ST14 | Suppressor of tumorigenicity 14 protein | Q9Y5Y6 | PRSS14 SNC19 TADG15 | 730 | Crystal Structure of Matriptase with Inhibitor CJ-730 | 2gv6 | 54.77 | | 46. |
251 | ST14 | Suppressor of tumorigenicity 14 protein | Q9Y5Y6 | PRSS14 SNC19 TADG15 | 3km | CRYSTAL STRUCTURE of MATRIPTASE in COMPLEX WITH INHIBITOR | 4r0i | 65.6 | | 300. |
252 | THRB | Prothrombin | P00734 | | unb | thrombin in complex with inhibitor | 2bdy | 78.07 | | 17. |
253 | THRB | Prothrombin | P00734 | | uet | Thrombin in complex with (2R)-2-(benzylsulfonylamino)-N-(2-((4- carbamimidoylphenyl)methylamino)-2-oxo-propyl)-3-phenyl-propanamide | 5afz | 78.77 | | no data |
254 | THRB | Prothrombin | P00734 | | tif | Human Thrombin In Complex With MI353 | 3uwj | 84.27 | | no data |
255 | THRB | Prothrombin | P00734 | | t87 | THROMBIN INHIBITOR COMPLEX | 1g30 | 67.9 | | 140. |
256 | THRB | Prothrombin | P00734 | | t76 | thrombin in complex with selective macrocyclic inhibitor | 1nt1 | 80.41 | | 1.3 |
257 | THRB | Prothrombin | P00734 | | t42 | HUMAN ALPHA-THROMBIN TERNARY COMPLEX WITH THE EXOSITE INHIBITOR HIRUGEN AND ACTIVE SITE INHIBITOR PHCH2OCO-D-DPA-PRO-BOROMPG | 1ai8 | 71.57 | | no data |
258 | THRB | Prothrombin | P00734 | | t15 | Crystal structure of thrombin in complex with inhibitor 15 | 3c1k | 75.09 | | 0.36 |
259 | THRB | Prothrombin | P00734 | | s04 | Human Thrombin in complex with MI004 | 3rmo | 78.42 | | no data |
260 | THRB | Prothrombin | P00734 | | s00 | Human Thrombin in complex with MI003 | 3rm2 | 82.72 | | no data |
261 | THRB | Prothrombin | P00734 | | ra8 | X-ray crystal structure of thrombin inhibited by synthetic cyanopeptide analogue RA-1008 | 1ypl | 75.31 | | no data |
262 | THRB | Prothrombin | P00734 | | nli | Discovery and Clinical Evaluation of RWJ-671818, a Thrombin Inhibitor with an Oxyguanidine P1 Motif | 3ldx | 81.22 | | no data |
263 | THRB | Prothrombin | P00734 | | na9 | Orally Active Thrombin Inhibitors in Complex with Thrombin Inh12 | 2a2x | 79.75 | | 20.2 |
264 | THRB | Prothrombin | P00734 | | n12 | orally active thrombin inhibitors in complex with thrombin and an exosite decapeptide | 2ank | 78.54 | | 47.3 |
265 | THRB | Prothrombin | P00734 | | mvf | Thrombin in complex with inhibitor | 4bao | 85.08 | | 4.29 |
266 | THRB | Prothrombin | P00734 | | miu | Alpha-thrombin complex with sulfated hirudin (residues 54-65) and L- Arginine template inhibitor CS107 | 1w7g | 82.97 | | 8000. |
267 | THRB | Prothrombin | P00734 | | mit | CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS | 1dwc | 79.67 | | 39. |
268 | THRB | Prothrombin | P00734 | | mid | CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS | 1dwd | 79.39 | | 6.6 |
269 | THRB | Prothrombin | P00734 | | mel | HUMAN THROMBIN-INHIBITOR COMPLEX | 1k22 | 82.29 | | 4. |
270 | THRB | Prothrombin | P00734 | | mel | Thrombin in complex with inhibitor | 4bah | 83.12 | | 2.01 |
271 | THRB | Prothrombin | P00734 | | m6s | Thrombin in complex with inhibitor | 4ban | 85.05 | | 2.43 |
272 | THRB | Prothrombin | P00734 | | m67 | Thrombin in complex with inhibitor | 4bak | 85.02 | | 1.22 |
273 | THRB | Prothrombin | P00734 | | m4z | Thrombin in complex with inhibitor | 4baq | 84.66 | | 0.98 |
274 | THRB | Prothrombin | P00734 | | m41 | Human Thrombin in complex with MI341 | 3rmn | 77.05 | | no data |
275 | THRB | Prothrombin | P00734 | | m34 | Human Thrombin In Complex With MI340 | 3t5f | 80.48 | | no data |
276 | THRB | Prothrombin | P00734 | | l86 | thrombin in complex with selective macrocyclic inhibitor at 1.8A | 1nm6 | 79.76 | | 0.09 |
277 | THRB | Prothrombin | P00734 | | ign | HUMAN THROMBIN-INHIBITOR COMPLEX | 1k21 | 79.51 | | 4.2 |
278 | THRB | Prothrombin | P00734 | | i50 | 2-(2-Chloro-6-Fluorophenyl)Acetamides as Potent Thrombin Inhibitors | 2r2m | 81.95 | | 47.1 |
279 | THRB | Prothrombin | P00734 | | goz | Thrombin in Complex with a D-Phe-Pro-diaminopyridine derivative | 6hsx | 87.68 | | no data |
280 | THRB | Prothrombin | P00734 | | dkk | Cyanofluorophenylacetamides as Orally Efficacious Thrombin Inhibitors | 3c27 | 83.34 | | no data |
281 | THRB | Prothrombin | P00734 | | d6j | Thrombin in complex with (2R)-2-(benzylsulfonylamino)-N-((1S)-2-((4- carbamimidoylphenyl)methylamino)-1-methyl-2-oxo-ethyl)-N-methyl-3- phenyl-propanamide ethane | 4ufg | 80.5 | | 7. |
282 | THRB | Prothrombin | P00734 | | cdo | Ternary complex of an orally active thrombin inhibitor with human thrombin and a c-terminal hirudin derived exo-sit inhibitor | 2anm | 79.34 | | 1.8 |
283 | THRB | Prothrombin | P00734 | | c7m | thrombin inhibitors | 2c8w | 82.11 | | 3.7 |
284 | THRB | Prothrombin | P00734 | | c5m | thrombin inhibitors | 2c8x | 82.85 | | 220. |
285 | THRB | Prothrombin | P00734 | | c1d | Design and Discovery of Novel, Potent Thrombin Inhibitors with a Solubilizing Cationic P1-P2-Linker | 2bxu | 86.26 | | 70. |
286 | THRB | Prothrombin | P00734 | | bzt | CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZOTHIOPHENE INHIBITOR 4 | 1d3d | 70.76 | | 0.81 |
287 | THRB | Prothrombin | P00734 | | bt3 | CRYSTAL STRUCTURE OF HUMAN APLHA-THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 3 | 1d3p | 71.16 | | 41. |
288 | THRB | Prothrombin | P00734 | | bt2 | CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 2 | 1d3q | 68.69 | | 290. |
289 | THRB | Prothrombin | P00734 | | bt1 | CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 1 | 1d3t | 67.33 | | no data |
290 | THRB | Prothrombin | P00734 | | bli | CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH A NOVEL BICYCLIC LACTAM INHIBITOR | 1jwt | 81.25 | | 14. |
291 | THRB | Prothrombin | P00734 | | 81a | Crystal Structure Analysis of a novel Oxyguanidine bound to Thrombin | 1t4u | 77.13 | | no data |
292 | THRB | Prothrombin | P00734 | | 6v2 | Thrombin in complex with (2R)-2-(benzylsulfonylamino)-N-(2-((4- carbamimidoylphenyl)methylamino)-2-oxo-ethyl)-N-methyl-3-phenyl- propanamide | 4uff | 80.59 | | 11. |
293 | THRB | Prothrombin | P00734 | | 6ov | Thrombin in complex with (S)-1-((R)-2-amino-3-cyclohexylpropanoyl)-N-(4-carbamimidoylbenzyl)pyrrolidine-2-carboxamide | 5jzy | 86.01 | | no data |
294 | THRB | Prothrombin | P00734 | | 4cp | Human thrombin complexed with fragment-based small molecules occupying the S1 pocket | 2bvr | 62.48 | | 200000. |
295 | THRB | Prothrombin | P00734 | | 3zd | Thrombin in complex with (2R)-2-(benzylsulfonylamino)-N-(2-((4- carbamimidoylphenyl)methylamino)-2-oxo-butyl)-3-phenyl-propanamide | 4ufe | 80.13 | | 7. |
296 | THRB | Prothrombin | P00734 | | 3sp | Orally active thrombin inhibitors | 2fes | 80.89 | | 0.98 |
297 | THRB | Prothrombin | P00734 | | 34p | orally active thrombin inhibitors | 2feq | 80.27 | | 1.39 |
298 | THRB | Prothrombin | P00734 | | 33u | Bisphenylic Thrombin Inhibitors | 2zo3 | 77.39 | | 0.1 |
299 | THRB | Prothrombin | P00734 | | 32u | Thrombin Mutant A190S in complex with (S)-1-(D-phenylalanyl)-N-(4-carbamimidoylbenzyl)pyrrolidine-2-carboxamide | 5mm6 | 87.53 | | no data |
300 | THRB | Prothrombin | P00734 | | 32u | Exploring Thrombin S1 pocket | 2zda | 86.32 | | 4. |
301 | THRB | Prothrombin | P00734 | | 31u | Thrombin Inhibition | 2znk | 84.62 | | no data |
302 | THRB | Prothrombin | P00734 | | 2ce | Human thrombin complexed with fragment-based small molecules occupying the S1 pocket | 2bvs | 67 | | 80000. |
303 | THRB | Prothrombin | P00734 | | 29u | Thrombin Inhibition | 2zgx | 85.25 | | 180. |
304 | THRB | Prothrombin | P00734 | | 170 | crystal structue of Thrombin in complex with a potent P1 heterocycle-Aryl based inhibitor | 1sl3 | 82.43 | | 0.0014 |
305 | THRB | Prothrombin | P00734 | | 166 | Novel Covalent Active Site Thrombin Inhibitors | 1qj1 | 89.18 | | 9. |
306 | THRB | Prothrombin | P00734 | | 165 | Novel Non-Covalent Thrombin Inhibitors Incorporating P1 4,5,6,7-Tetrahydrobenzothiazole Arginine Side Chain Mimetics | 1sb1 | 76.12 | | 128. |
307 | THRB | Prothrombin | P00734 | | 163 | Human Thrombin complexed with a d-Phe-Pro-Arg-type Inhibitor and a C-terminal Hirudin derived exo-site inhibitor | 1o0d | 76.79 | | 6.2 |
308 | THRB | Prothrombin | P00734 | | 162 | D-Phe-Pro-Arg-Type Thrombin Inhibitor | 1nzq | 80.11 | | 11. |
309 | THRB | Prothrombin | P00734 | | 121 | A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE | 1ghy | 93.33 | | 8. |
310 | THRB | Prothrombin | P00734 | | 110 | CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN COMPLEXED WITH BCH-10556 AND EXOSITE-DIRECTED PEPTIDE | 1g37 | 78.22 | | 0.1 |
311 | THRB | Prothrombin | P00734 | | 0ze | HUMAN THROMBIN COMPLEXED WITH NOVEL SYNTHETIC PEPTIDE MIMETIC INHIBITOR AND HIRUGEN | 1b5g | 74.43 | | 10. |
312 | THRB | Prothrombin | P00734 | | 0kv | Thrombin inhibitors with rigid tripeptidyl aldehydes | 1ca8 | 79.29 | | 0.32 |
313 | THRB | Prothrombin | P00734 | | 0iv | THROMBIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES | 1bb0 | 80.34 | | 4.4 |
314 | THRB | Prothrombin | P00734 | | 00r | STRUCTURE OF THROMBIN COMPLEXED WITH SELECTIVE NON-ELECTROPHILIC INHIBITORS HAVING CYCLOHEXYL MOIETIES AT P1 | 1d6w | 79.68 | | 1100. |
315 | THRB | Prothrombin | P00734 | | 00n | THROMBIN COMPLEXED WITH A BETA-MIMETIC THIAZOLE-CONTAINING INHIBITOR | 1a61 | 84.59 | | 2.4 |
316 | THRB | Prothrombin | P00734 | | 00l | HUMAN THROMBIN COMPLEXED WITH NOVEL SYNTHETIC PEPTIDE MIMETIC INHIBITOR AND HIRUGEN | 1a5g | 80.53 | | 0.071 |
317 | THRB | Prothrombin | P00734 | | 00k | THROMBIN COMPLEXED WITH HIRUGEN AND A BETA-STRAND MIMETIC INHIBITOR | 1a46 | 76.88 | | 2000. |
318 | THRB | Prothrombin | P00734 | | bai | RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES | 1c1u | 81.66 | | 5.6 |
319 | THRB | Prothrombin | P00734 | | bpp | CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH 5-AMIDINOINDOLE-4-BENZYLPIPERIDINE INHIBITOR | 1d4p | 83.66 | | 500. |
320 | THRB | Prothrombin | P00734 | | r11 | THROMBIN INHIBITOR COMPLEX | 1g32 | 79.29 | | 780. |
321 | THRB | Prothrombin | P00734 | | c24 | Thrombin Inhibitor Complex | 1kts | 78.73 | | no data |
322 | THRB | Prothrombin | P00734 | | c02 | Thrombin inhibitor complex | 1ktt | 83.46 | | 1500. |
323 | THRB | Prothrombin | P00734 | | cdb | thrombin-hirugen_l-378,650 | 1mu8 | 82.28 | | 1. |
324 | THRB | Prothrombin | P00734 | | cdd | Thrombin-Hirugen-L405,426 | 1mue | 81.32 | | 2.3 |
325 | THRB | Prothrombin | P00734 | | cr9 | Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala190 Protease (Ala190 uPA) | 1o5g | 83.14 | | 11000. |
326 | THRB | Prothrombin | P00734 | | fsn | COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH A DESIGNED FLUORINATED INHIBITOR | 1oyt | 85.64 | | 57. |
327 | THRB | Prothrombin | P00734 | | ppx | CRYSTAL STRUCTURE OF THROMBIN COMPLEXED WITH AN GUANIDINE-MIMETIC INHIBITOR | 1qbv | 81.05 | | 4100. |
328 | THRB | Prothrombin | P00734 | | 167 | Novel Covalent Active Site Thrombin Inhibitors | 1qj6 | 85.39 | | 18. |
329 | THRB | Prothrombin | P00734 | | gr1 | Novel Covalent Active Site Thrombin Inhibitors | 1qj7 | 85.82 | | 8. |
330 | THRB | Prothrombin | P00734 | | 14a | Crystal Structure Analysis of a novel Oxyguanidine bound to Thrombin | 1t4v | 80.81 | | 21. |
331 | THRB | Prothrombin | P00734 | | 176 | Crystal structure of thrombin in complex with compound 1 | 1ta2 | 78.16 | | 3. |
332 | THRB | Prothrombin | P00734 | | 177 | Crystal structure of thrombin in complex with compound 14b | 1ta6 | 81.38 | | 0.74 |
333 | THRB | Prothrombin | P00734 | | min | ALPHA-THROMBIN COMPLEXED WITH HIRUGEN | 1tom | 80.11 | | 5. |
334 | THRB | Prothrombin | P00734 | | i11 | BOVINE THROMBIN--BM51.1011 COMPLEX | 1uvs | 78.23 | | 4000. |
335 | THRB | Prothrombin | P00734 | | shy | Complex of thrombin with designed inhibitor 7165 | 1vzq | 85.96 | | 36. |
336 | THRB | Prothrombin | P00734 | | uir | Thrombin Inhibitor Complex | 1ypg | 83.51 | | 10. |
337 | THRB | Prothrombin | P00734 | | uip | Thrombin Inhibitor Complex | 1ype | 84.87 | | 8. |
338 | THRB | Prothrombin | P00734 | | uib | Thrombin Inhibitor Complex | 1ypj | 85.67 | | 95. |
339 | THRB | Prothrombin | P00734 | | l17 | thrombin and P2 pyridine N-oxide inhibitor complex structure | 1z71 | 83.97 | | 0.66 |
340 | THRB | Prothrombin | P00734 | | 382 | thrombin in complex with an oxazolopyridine inhibitor 21 | 1zgi | 79.76 | | 4600. |
341 | THRB | Prothrombin | P00734 | | 062 | Thrombin in complex with an azafluorenyl inhibitor 23b | 1zrb | 77.94 | | no data |
342 | THRB | Prothrombin | P00734 | | c2d | Design and Discovery of Novel, Potent Thrombin Inhibitors with a Solubilizing Cationic P1-P2-Linker | 2bxt | 88.12 | | 3. |
343 | THRB | Prothrombin | P00734 | | c4m | thrombin inhibitors | 2c93 | 80.11 | | 12000. |
344 | THRB | Prothrombin | P00734 | | esh | Complex of recombinant human thrombin with an inhibitor | 2cf8 | 84.78 | | 8. |
345 | THRB | Prothrombin | P00734 | | 348 | Complex of recombinant human thrombin with an inhibitor | 2cf9 | 84.23 | | 15. |
346 | THRB | Prothrombin | P00734 | | f25 | Complex of Recombinant Human Thrombin with a Designed Inhibitor | 2cn0 | 85.86 | | 22. |
347 | THRB | Prothrombin | P00734 | | 701 | Human Thrombin Hirugen Inhibitor complex | 2jh0 | 80.95 | | 2. |
348 | THRB | Prothrombin | P00734 | | 895 | Human Thrombin Hirugen Inhibitor complex | 2jh5 | 79.31 | | 367. |
349 | THRB | Prothrombin | P00734 | | 894 | Human Thrombin Hirugen Inhibitor complex | 2jh6 | 80.06 | | 17. |
350 | THRB | Prothrombin | P00734 | | 896 | Thrombin-hirugen-gw473178 ternary complex at 1.32A resolution | 2uuj | 85.75 | | no data |
351 | THRB | Prothrombin | P00734 | | 897 | Thrombin-hirugen-gw420128 ternary complex at 1.39A resolution | 2uuk | 68.1 | | no data |
352 | THRB | Prothrombin | P00734 | | i25 | Thrombin with 3-cycle no F | 2v3h | 64 | | no data |
353 | THRB | Prothrombin | P00734 | | i26 | Thrombin with 3-cycle with F | 2v3o | 80.41 | | no data |
354 | THRB | Prothrombin | P00734 | | 50u | Exploring thrombin S3 pocket | 2zg0 | 83.78 | | no data |
355 | THRB | Prothrombin | P00734 | | 45u | Exploring thrombin S3 pocket | 2zfq | 85.3 | | no data |
356 | THRB | Prothrombin | P00734 | | 46u | Exploring thrombin S3 pocket | 2zfr | 80.27 | | no data |
357 | THRB | Prothrombin | P00734 | | 49u | Exploring thrombin S3 pocket | 2zhf | 81.63 | | no data |
358 | THRB | Prothrombin | P00734 | | 37u | Exploring Thrombin S1 pocket | 2zdv | 83.03 | | no data |
359 | THRB | Prothrombin | P00734 | | 51u | Exploring Thrombin S1 Pocket | 2zf0 | 83.8 | | no data |
360 | THRB | Prothrombin | P00734 | | 19u | Thrombin Inibition | 2zfp | 82.43 | | 6800. |
361 | THRB | Prothrombin | P00734 | | 12u | Exploring thrombin S3 pocket | 2zhw | 81.87 | | no data |
362 | THRB | Prothrombin | P00734 | | 21u | Thrombin Inhibition | 2zgb | 84.97 | | no data |
363 | THRB | Prothrombin | P00734 | | 27u | Thrombin Inhibition | 2zhq | 83.76 | | no data |
364 | THRB | Prothrombin | P00734 | | 24u | Thrombin Inhibition | 2zi2 | 83.75 | | no data |
365 | THRB | Prothrombin | P00734 | | 26u | Thrombin Inhibition | 2ziq | 85.87 | | no data |
366 | THRB | Prothrombin | P00734 | | 11u | Human thrombin-in complex with UB-THR11 | 3biv | 81.27 | | no data |
367 | THRB | Prothrombin | P00734 | | 13u | Exploring thrombin S3 pocket | 2zhe | 82.77 | | no data |
368 | THRB | Prothrombin | P00734 | | 44u | Crystal structure of thrombin in complex with inhibitor | 3da9 | 73.73 | | 3100. |
369 | THRB | Prothrombin | P00734 | | 23u | Thrombin Mutant A190S in complex with (S) -1 - ((R) -2-amino-3,3-diphenylpropanoyl) -N- (3-chlorobenzyl) pyrrolidine-2-carboxamide | 5mjt | 81.28 | | no data |
370 | THRB | Prothrombin | P00734 | | 23u | Bisphenylic Thrombin Inhibitors | 3dhk | 80.1 | | 47. |
371 | THRB | Prothrombin | P00734 | | 16u | Understanding Thrombin Inhibition | 3dt0 | 84.51 | | no data |
372 | THRB | Prothrombin | P00734 | | 64u | Understanding Thrombin Inhibition | 3dux | 83.88 | | 100. |
373 | THRB | Prothrombin | P00734 | | 91u | Thrombin Inhibition | 3f68 | 78.75 | | 8700. |
374 | THRB | Prothrombin | P00734 | | 10u | Human thrombin-in complex with UB-THR10 | 3biu | 84.73 | | no data |
375 | THRB | Prothrombin | P00734 | | 99p | Thrombin Inhibition by Pyridin Derivatives | 3p17 | 85.58 | | 33400. |
376 | THRB | Prothrombin | P00734 | | 10p | Thrombin Inhibition by Pyridin Derivatives | 3qto | 87.77 | | 74800. |
377 | THRB | Prothrombin | P00734 | | 06p | Thrombin Inhibition by Pyridin Derivatives | 3qtv | 87.76 | | 22500. |
378 | THRB | Prothrombin | P00734 | | 98p | Thrombin Inhibition by Pyridin Derivatives | 3qwc | 81.93 | | 55400. |
379 | THRB | Prothrombin | P00734 | | 02p | Thrombin Inhibition by Pyridin Derivatives | 3qx5 | 85.75 | | 63500. |
380 | THRB | Prothrombin | P00734 | | s28 | Human Thrombin in complex with MI328 | 3rlw | 85.8 | | no data |
381 | THRB | Prothrombin | P00734 | | s29 | Human Thrombin in complex with MI329 | 3rly | 91.29 | | no data |
382 | THRB | Prothrombin | P00734 | | s54 | Human Thrombin in complex with MI354 | 3rm0 | 53.24 | | no data |
383 | THRB | Prothrombin | P00734 | | m31 | Human Thrombin in complex with MI331 | 3rml | 85.83 | | no data |
384 | THRB | Prothrombin | P00734 | | m32 | Human Thrombin in complex with MI332 | 3rmm | 77.12 | | no data |
385 | THRB | Prothrombin | P00734 | | p97 | Human Thrombin In Complex With UBTHR97 | 3sha | 83.83 | | 2600. |
386 | THRB | Prothrombin | P00734 | | b01 | Human Thrombin In Complex With UBTHR101 | 3shc | 82.99 | | 1900. |
387 | THRB | Prothrombin | P00734 | | b03 | Human Thrombin In Complex With UBTHR103 | 3si3 | 87.17 | | 69300. |
388 | THRB | Prothrombin | P00734 | | b04 | Human Thrombin In Complex With UBTHR104 | 3si4 | 86.81 | | 132200. |
389 | THRB | Prothrombin | P00734 | | p05 | Human Thrombin In Complex With UBTHR105 | 3sv2 | 87.27 | | 64000. |
390 | THRB | Prothrombin | P00734 | | 0bm | Human alpha-thrombin complexed with N-(methylsulfonyl)-D-phenylalanyl-N-((1-carbamimidoyl-4-piperidinyl)methyl)-l-prolinamide (BMS-189664) | 3tu7 | 83.15 | | 8.17 |
391 | THRB | Prothrombin | P00734 | | 9mu | Human thrombin - inhibitor complex | 4az2 | 77.64 | | 47. |
392 | THRB | Prothrombin | P00734 | | mm9 | Thrombin in complex with inhibitor | 4bam | 84.9 | | 1.14 |
393 | THRB | Prothrombin | P00734 | | n6l | Thrombin in complex with 1-(2R)-2-amino-3-phenyl-propanoyl-N-(2, 5dichlorophenyl)methylpyrrolidine-2-carboxamide | 4udw | 85.37 | | no data |
394 | THRB | Prothrombin | P00734 | | 45s | Thrombin in complex with (S)-(4-chloro-2-((1-(5-methyl-1H-pyrrole-2-carbonyl)pyrrolidine-2-carboxamido)methyl)phenyl)methanaminium | 4yes | 83.16 | | 9.6 |
395 | THRB | Prothrombin | P00734 | | sjr | Thrombin in complex with 4-Methoxy-N-(2-pyridinyl)benzamide | 5af9 | 77.86 | | no data |
396 | THRB | Prothrombin | P00734 | | 6th | Thrombin in complex with (S)-1-((R)-2-amino-3-cyclohexylpropanoyl)-N-(5-chloro-2-(hydroxymethyl)benzy l)pyrrolidine-2-carboxamide | 5lce | 86.84 | | no data |
397 | THRB | Prothrombin | P00734 | | 71u | Thrombin in complex with (S)-1-((R)-2-amino-3-cyclohexylpropanoyl)-N-(2-(aminomethyl)-5-chlorobenzyl) pyrrolidine-2-carboxamide | 5lpd | 88.43 | | no data |
398 | THRB | Prothrombin | P00734 | | 22u | Thrombin in complex with Inhibitor | 2zc9 | 84.45 | | 180. |
399 | THRB | Prothrombin | P00734 | | 22u | Thrombin Mutant A190S in complex with (S)-1-(D-phenylalanyl)-N-(3-chlorobenzyl)pyrrolidine-2-carboxamide | 5mls | 85.35 | | no data |
400 | THRB | Prothrombin | P00734 | | apa | CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN COMPLEXED WITH HIRUGEN AND P-AMIDINOPHENYLPYRUVATE AT 1.6 ANGSTROMS RESOLUTION | 1aht | 89.4 | | 620. |
401 | TPA | Tissue-type plasminogen activator | P00750 | | bba | CATALYTIC DOMAIN OF HUMAN TWO-CHAIN TISSUE PLASMINOGEN ACTIVATOR COMPLEX OF A BIS-BENZAMIDINE | 1a5h | 77.31 | | 500. |
402 | TRYB2 | Tryptase beta-2 | P20231 | TPS2 | c4a | Human beta tryptase II with inhibitor CRA-28427 | 2fs9 | 72.82 | | 3. |
403 | TRYB2 | Tryptase beta-2 | P20231 | TPS2 | c3a | Human beta-tryptase II with inhibitor CRA-29382 | 2fs8 | 73.09 | | 25. |
404 | TRYB2 | Tryptase beta-2 | P20231 | TPS2 | c3a | human beta tryptase II complexed with activated ketone inhibitor CRA-29382 | 2fxr | 74.37 | | 25. |
405 | TRYB2 | Tryptase beta-2 | P20231 | TPS2 | 5am | Human beta II tryptase with inhibitor CRA-27592 | 2gdd | 69.27 | | no data |
406 | TRYB2 | Tryptase beta-2 | P20231 | TPS2 | apa | HUMAN BETA-TRYPTASE: A RING-LIKE TETRAMER WITH ACTIVE SITES FACING A CENTRAL PORE | 1a0l | 87.15 | | no data |
407 | TRYB2 | Tryptase beta-2 | P20231 | TPS2 | 5ta | TRYPTASE B2 IN COMPLEX WITH 5-(3-Aminomethyl-phenoxymethyl)-3-[3-(2-chloro-pyridin-3-ylethynyl)-phenyl]-oxazolidin-2-one; compound with trifluoro-acetic acid | 5f03 | 71.01 | | no data |
408 | UROK | Urokinase-type plasminogen activator | P00749 | | ui1 | Substituted 2-Naphthamidine Inhibitors of Urokinase | 1sqa | 70.92 | | 0.62 |
409 | UROK | Urokinase-type plasminogen activator | P00749 | | hmx | uPA-HMA | 5za7 | 75.89 | | no data |
410 | UROK | Urokinase-type plasminogen activator | P00749 | | h55 | The crystal structure of uPA in complex with HMA-55F | 6ag7 | 70.79 | | no data |
411 | UROK | Urokinase-type plasminogen activator | P00749 | | eau | uPA-6F-HMA | 5zae | 74.51 | | no data |
412 | UROK | Urokinase-type plasminogen activator | P00749 | | amr | UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-AMILORIDE COMPLEX | 1f5l | 84.2 | | 5300. |
413 | UROK | Urokinase-type plasminogen activator | P00749 | | 9xc | Crystal structure of uPA in complex with 3,5-bis(azanyl)-N-carbamimidoyl-6-(2,4-dimethoxypyrimidin-5-yl)pyrazine-2-carboxamide | 6ag3 | 59.7 | | no data |
414 | UROK | Urokinase-type plasminogen activator | P00749 | | 9x9 | uPA-HMA | 6ag2 | 74.71 | | no data |
415 | UROK | Urokinase-type plasminogen activator | P00749 | | 32i | uPA-31F | 5zaj | 71.21 | | no data |
416 | UROK | Urokinase-type plasminogen activator | P00749 | | 28i | uPA-BB2-28F | 5zaf | 67.15 | | no data |
417 | UROK | Urokinase-type plasminogen activator | P00749 | | 239 | Substituted 2-Naphthamidine Inhibitors of Urokinase | 1owh | 75.09 | | 40. |
418 | UROK | Urokinase-type plasminogen activator | P00749 | | 239 | Crystal Structure of the Urokinase | 4fuc | 78.29 | | no data |
419 | UROK | Urokinase-type plasminogen activator | P00749 | | 123 | A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE | 1gi9 | 66.08 | | 6000. |
420 | UROK | Urokinase-type plasminogen activator | P00749 | | 133 | ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS | 1gj8 | 72.52 | | 110. |
421 | UROK | Urokinase-type plasminogen activator | P00749 | | 134 | ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS | 1gj9 | 76.7 | | no data |
422 | UROK | Urokinase-type plasminogen activator | P00749 | | 135 | ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS | 1gja | 78.16 | | 3800. |
423 | UROK | Urokinase-type plasminogen activator | P00749 | | 136 | ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS | 1gjd | 76.14 | | 6000. |
424 | UROK | Urokinase-type plasminogen activator | P00749 | | 655 | Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors | 1o3p | 71.62 | | 220. |
425 | UROK | Urokinase-type plasminogen activator | P00749 | | cr9 | Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala190 Protease (Ala190 uPA) | 1o5c | 72.21 | | 6000. |
426 | UROK | Urokinase-type plasminogen activator | P00749 | | 497 | Substituted 2-Naphthamidine inhibitors of urokinase | 1owd | 64.3 | | 6.3 |
427 | UROK | Urokinase-type plasminogen activator | P00749 | | 426 | Substituted 2-Naphthamidine Inhibitors of Urokinase | 1owi | 69.14 | | 28. |
428 | UROK | Urokinase-type plasminogen activator | P00749 | | 303 | Substituted 2-Naphthamidine Inhibitors of Urokinase | 1owk | 64.19 | | 23.5 |
429 | UROK | Urokinase-type plasminogen activator | P00749 | | 745 | Substituted 2-Naphthamadine inhibitors of Urokinase | 1u6q | 70.13 | | 1310. |
430 | UROK | Urokinase-type plasminogen activator | P00749 | | 4pg | Urokinase plasminogen activator B-chain-GPPE complex | 2r2w | 82.6 | | 34000. |
431 | UROK | Urokinase-type plasminogen activator | P00749 | | l1r | Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator | 2vip | 72.23 | | 5200. |
432 | UROK | Urokinase-type plasminogen activator | P00749 | | d55 | Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator | 2viq | 71.25 | | 1300. |
433 | UROK | Urokinase-type plasminogen activator | P00749 | | vg2 | Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator | 2viv | 63.21 | | 520. |
434 | UROK | Urokinase-type plasminogen activator | P00749 | | d56 | Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator | 2viw | 68.78 | | 72. |
435 | UROK | Urokinase-type plasminogen activator | P00749 | | qgg | UROKINASE-TYPE PLASMINOGEN ACTIVATOR INHIBITOR COMPLEX WITH A 1-(7- SULPHOAMIDOISOQUINOLINYL)GUANIDINE | 2vnt | 87.77 | | 9.9 |
436 | UROK | Urokinase-type plasminogen activator | P00749 | | que | Crystal structure of uPA in complex with quercetin | 5xg4 | 75.15 | | 7000. |
437 | UROK | Urokinase-type plasminogen activator | P00749 | | 7up | Crystal Structure of the Urokinase | 4fue | 74.03 | | no data |
438 | UROK | Urokinase-type plasminogen activator | P00749 | | 9xf | Crystal structure of uPA in complex with 3,5-bis(azanyl)-6-(1-benzofuran-2-yl)-N-carbamimidoyl-pyrazine-2- carboxamide | 6ag9 | 74.71 | | no data |
439 | UROK | Urokinase-type plasminogen activator | P00749 | | 09i | uPA-NU-09F | 5zc5 | 71.8 | | no data |
440 | UROK | Urokinase-type plasminogen activator | P00749 | | 30i | uPA-BB2-30F | 5zah | 65.61 | | no data |
441 | UROK | Urokinase-type plasminogen activator | P00749 | | 94i | uPA-BB2-94F | 5zag | 69.17 | | no data |
442 | UROK | Urokinase-type plasminogen activator | P00749 | | 50i | uPA-BB2-50F | 5za9 | 68.34 | | no data |
443 | UROK | Urokinase-type plasminogen activator | P00749 | | 27i | uPA-BB2-27F | 5za8 | 66.78 | | no data |
444 | UROK | Urokinase-type plasminogen activator | P00749 | | 11e | Synthesis of a Weak Basic uPA Inhibitor and Crystal Structure of Complex with uPA | 4h42 | 76.34 | | 341000. |
445 | UROK | Urokinase-type plasminogen activator | P00749 | | 1u9 | Crystal Structure of the Urokinase | 4fuj | 68.44 | | no data |
446 | UROK | Urokinase-type plasminogen activator | P00749 | | ui3 | Crystal Structure of the Urokinase | 4fui | 76.89 | | no data |
447 | UROK | Urokinase-type plasminogen activator | P00749 | | 9up | Crystal Structure of the Urokinase | 4fug | 83.06 | | no data |
448 | UROK | Urokinase-type plasminogen activator | P00749 | | 8up | Crystal Structure of the Urokinase | 4fuf | 79.94 | | no data |
449 | UROK | Urokinase-type plasminogen activator | P00749 | | 1up | Crystal Structure of the Urokinase | 4fu7 | 79.58 | | no data |
450 | UROK | Urokinase-type plasminogen activator | P00749 | | ui3 | Substituted 2-Naphthamidine Inhibitors of Urokinase | 1sqt | 77.82 | | 630. |
451 | UROK | Urokinase-type plasminogen activator | P00749 | | ui2 | Substituted 2-Naphthamidine Inhibitors of Urokinase | 1sqo | 85.39 | | 35. |